Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-10-03
2006-10-03
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S042000, C514S043000, C514S045000, C514S048000, C514S049000, C514S052000, C514S885000, C424S001110, C424S001730, C424S001770, C424S009810, C424S278100, C424S280100, C536S022100, C536S023100, C536S024500, C536S025600
Reexamination Certificate
active
07115579
ABSTRACT:
The invention provides methods for modulating the immune response caused by CpG dinucleotide-containing compounds. The methods according to the invention enables both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications.
REFERENCES:
patent: 5149798 (1992-09-01), Agrawal et al.
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: WO 98/49288 (1998-11-01), None
patent: WO 01/12804 (2001-02-01), None
McCluskie et al., “Cutting Edge: CpG DNA is a Potent Enhancer of Systemic and Mucosal Immune Responses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice”, J. Immunol., vol. 161, pp. 4463-4466, 1998.
Kuramoto et al., “Oligonucleotide Sequences Required for Natural Killer Cell Activation”, Jpn. J. Cancer Res., vol. 83, pp. 1128-1131, Nov. 1992.
Khorana et al. (1972) “Studies on Polynucleotides,”J. Molec. Biol. 72:209.
Reese (1978) “The Chemical Synthesis of Oligo- and Poly-Nucleotides By The Phosporotriester Approach,”Tetrahedron34:3143-3179.
Beaucage e tal. (1981) “Deoxynucleoside Phosphoramidites—A New Class of Key Intermediates for Deoxypolynucleotide Synthesis,”Tetrahedron Lett. 22:1859-1862.
Connolly et al. (1984) “Synthesis and Characterization of an Octanucleotide Containing the EcoRI Recognition Sequence With A Phosphorothioate Group At The Cleavage Site,”Biochemistry23:3443.
Agrawal et al. (1987) “Oligodeoxynucleotise Methylphosphonates: Synthesis and Enzymic Degradation,”Tetrahedron Lett. 28(31):3539-3542.
Jager et al. (1988) “Oligonucleotide N-Alkylphosphoroamidates: Synthesis and Bindning to Polynucleotides,”Biochemistry27:7237.
Agrawal et al. (1988) Oligodeoxynucleoside Phosphoroamidates and Phosporothioates As Inhibitors of Human Immunodeficiency Virus,Proc. Natl. Acad. Sci. USA85:7079-7083.
Zon et al. (1991) “Phosphorothioate Oligonculeotides”Oligonucleotides and Analogues: A Practical Approachpp. 87-108.
Agrawal (1992) “Antisense Oligonucleotides as Antiviral Agents,”Trends in Biotechnology10:152-158.
Kuramoto et al. (1992) “Oligonucleotide Sequences Required For Natural Killer Cell Activation,”Jpn. J. Cancer Res. 83:1128-1131.
Zon (1993) “Protocols for Oliognucleotides and Analogs,”Methods in Molecular Biologyvol. 20, pp. 165-189.
McIntyre et al. (1993) “A Sense Phosphorothioate Oligonucleotide Directed to the Initiation Codon of Transcription Factor NF-kB p65 Causes Sequence-Specific Immune Stimulation,”Antisense Res. Dev. 3:309-322.
Agrawal et al. (1995) “Modified Oligonucleotides as Therapeutic and Diagnostic Agents,”Curr.Opin.Biotechnol. 6:12-19.
Crooke (1998) “An Overview of Progress in Antisense Therapeutics,”Antisense Nucleic Acid Drug Dev. 8:115-122.
Krieg et al. (1995) “CpG Motifs In Bacterial DNA Trigger Direct B-Cell Activation,”Nature371:546-549.
Liang et al. (1996) “Activation of Human B Cells By Phosphorothioate Oligodeoxynucleotides,,”J. Clin. Invest. 98:1119-1129.
McCluskie et al. (1998) “Cutting Edge: CpG DNA Is A Potent Enhancer of Systemic and Mucosal Immune Responses Against Hepatitis B Surface Antigen with Intranasal Administration to Mice,”J. Immunol. 161:4463-4466.
Moldoveanu et al. (1998) “CpG DNA, A Novel Immune Enhancer for Systemic and Mucosal Immunization With Influenza Virus,”Vaccine16:1216-1224.
Agrawal et al. (2000) “Antisense Therapeutics: Is It As Simple As Complementary Base Recognition?”Mol. Med. Today6:72-81.
Zhao, Q. et al.,Bioorganic&Medicinal Chemistry, “Site of Chemical Modifications in CpG Containing Phosphorothioate Oligonucleotide Modulates Its Immunostimulatory Activity”, pp. 3453-3458, 1999.
Moldoveanu, Z. et al.,Vaccine, “CpG DNA, a Novel Immune Enhancer for Systematic and Mucosal Immunization With Influenza Virus”, 16:1216-1224, 1998.
Krieg, Arthur M.,Applied Antisense Oligonucleotide Technology, “Leukocyte Stimulation By Oligodeoxynucleotides”, pp. 431-448, 1998.
Kandimalla, E.R. et al.,Bioorganic&Medicinal Chemistry, “Effect of Chemical Modifications of Cytosine and Guanine in a CpG-Motif of Oligonucleotides: Structure-Immunostimulatory Activity Relationships”, pp. 807-813, 2001.
Ekambar, D.Y. et al.,Bioorganic&Medicinal Chemistry, “Modulation of Immunostimulatory Activity of CpG Oligonucleotides by Site-Specific Deletion of Nucleobases”, pp. 2263-2267, 2001.
Agrawal Sudhir
Kandimalla Ekambar
Idera Pharmaceuticals Inc.
Jiang Shaojia Anna
Keown & Associates
McIntosh Traviss C.
LandOfFree
Modulation of oligonucleotide CpG-mediated immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of oligonucleotide CpG-mediated immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of oligonucleotide CpG-mediated immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3718061